<DOC>
	<DOCNO>NCT01149902</DOCNO>
	<brief_summary>The purpose study determine safety feasibility Chemo-Immunotherapy use cyclophosphamide , docetaxel , OK-432 , autologous immature dendritic cell patient relapse refractory head neck squamous cell carcinoma .</brief_summary>
	<brief_title>Study Chemo-Immunotherapy Head Neck Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Picibanil</mesh_term>
	<criteria>1 . The patient relapse refractory head neck squamous cell carcinoma 2 . 20 year old 3 . ECOG performance status 01 4 . More 4 week must elapse time radiation therapy last dose chemotherapy 5 . Tumor lesion accessible intratumoral dendritic cell injection 6 . Patients able oral ingestion 7 . Patients must normal organ marrow function follow : Hb &gt; 9.0 mg/dl Ht &gt; 25 % WBC &gt; 4000/mm3 Platelet count &gt; 100,000/mm3 TBil &lt; 1.5mg/dl GOT &lt; x2.5 institutional upper limit normal GPT &lt; x2.5 institutional upper limit normal Creatinin &lt; 1.5mg/dl 8. sign inform consent 1 . Less 20 year 2 . Patients test positive Hepatitis B virus , Hepatitis C virus HIV . 3 . Patients clinically active infection 4 . Patients uncontrolled concurrent illness include cardiovascular disease , pulmonary disease , bleed tendency 5 . Concomitant malignant disease , brain metastasis 6 . Psychiatric illness 7 . Treatment steroids 8 . Decision unsuitableness physician</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
</DOC>